Beijing Institute of Heart, Lung and Blood Vessel Diseases
25
3
3
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 25 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (25)
Comprehensive Geriatric Assessment in Chronic Disease Management for Older Adults in China: A Registry Study （CGACDM - Older Adults in China）
Role: collaborator
Diagnosis and Prognosis for Aortic Aneurysm aNd Dissection in Anzhen(DPANDA) Study
Role: lead
A Registry Study of Biomarkers in Ischemic Heart Disease ( BIOMS-IHD )
Role: lead
A Registry Study of Biomarkers in Heart Valve Disease
Role: lead
A Registry Study on Genetics and Biomarkers of Acute Coronary Syndrome
Role: lead
Baseline Investigation of Patients With Cardiac Arrest in China
Role: collaborator
A Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA)
Role: lead
A Registry Study of Biomarkers in Mitral Valve Disease (BIOMS-MVD)
Role: lead
China Diabetes Cardiovascular Initiative
Role: lead
CCC Project- Acute Coronary Syndrome
Role: lead
CCC Project - Atrial Fibrillation
Role: lead
A Registry Study on Biomarkers of Pulmonary Embolism
Role: lead
Chinese Multi-provincial Cohort Study-Beijing Project
Role: lead
Prognosis and Integrative Assessment of Aortic Coarctation Patients in China
Role: lead
Multi-provincial Cohort for Hypertension (MUCH)
Role: lead
A Registry Study of Biomarkers in Progression of Acute Heart Failure(BIOMS-POAHF)
Role: lead
Association Between S-LAAO and Adverse Cardiovascular Events Among Patients Undergoing Coronary Artery Bypass Grafting.
Role: lead
A Registry Study on Serumal Biomarkers About Adverse Events in Patients Undergoing Coronary Artery Bypass Grafting.
Role: lead
Prognostic Value of Plasma Biomarkers Among Patients With Hypertension
Role: lead
Prognostic Risk of Patients With Essential Hypertension for Cardiovascular Events (PROSPECT)
Role: lead